Is iguratimod safe for a breastfeeding mother with rheumatoid arthritis?

Iguratimod Safety During Breastfeeding

Iguratimod should not be used during breastfeeding due to the complete absence of safety data in lactating women and nursing infants.

Evidence Gap and Clinical Reasoning

• No major rheumatology guidelines (including the 2020 American College of Rheumatology guidelines on reproductive health) provide any recommendations regarding iguratimod use during lactation 1

• The ACR guidelines comprehensively address breastfeeding compatibility for conventional DMARDs, biologics, and small molecules, but iguratimod is notably absent from all recommendations 1

• Published clinical trials and real-world studies of iguratimod have not evaluated safety during breastfeeding or measured drug transfer into breast milk 2, 3

Safer Alternative DMARDs for Breastfeeding

If disease control is needed during lactation, transition to evidence-based breastfeeding-compatible medications:

Strongly Recommended Options

• Hydroxychloroquine - strongly recommended as compatible with breastfeeding with robust safety data 1, 4
• Sulfasalazine - strongly recommended as compatible (up to 2g daily with folic acid supplementation) 1, 4
• TNF inhibitors (adalimumab, etanercept, infliximab, etc.) - strongly recommended with minimal breast milk transfer 1, 4

Conditionally Recommended Options

• Azathioprine - conditionally recommended (up to 2 mg/kg/day) with negligible infant exposure 1, 5, 4
• NSAIDs (ibuprofen, naproxen) - conditionally recommended for symptomatic management 5, 4

Medications to Avoid

• Methotrexate - conditionally recommended against due to potential neonatal tissue accumulation 1, 5, 4
• Leflunomide - strongly contraindicated during breastfeeding 1, 4

Clinical Decision Algorithm

1. Discontinue iguratimod before initiating breastfeeding due to unknown safety profile
2. Assess disease severity to determine if DMARD therapy is required versus symptomatic management alone 5
3. For mild/well-controlled disease: Consider NSAIDs alone (ibuprofen or naproxen) 5, 4
4. For active disease requiring DMARD: Transition to hydroxychloroquine, sulfasalazine, or TNF inhibitor based on disease characteristics 1, 5, 4
5. Collaborate with pediatrics when making final medication decisions, particularly for infants under 6 weeks 5, 4

Important Caveats

• Iguratimod is a small-molecule DMARD that likely crosses into breast milk based on its pharmacologic properties, similar to other small molecules 1
• The drug's mechanism of inhibiting multiple inflammatory cytokines and affecting B-cell function raises theoretical concerns about infant immune development 6, 7, 8
• Women should be counseled about breastfeeding-compatible alternatives before conception to allow adequate washout and transition planning 1